Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193423 | 0.88 | ADORA3 (0.55) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL25401067 | 0.87 | ADORA3 (0.51) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL15070633 | 0.87 | ADORA3 (0.51) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL12851722 | 0.85 | ADORA3 (0.53) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL562134 | 0.82 | ADORA3 (0.59) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL562135 | 0.82 | ADORA3 (0.59) | HINT1ADORA3TAAR1HPGDNT5E | |
| SCHEMBL23394181 | 0.79 | ADORA3 (0.53) | HINT1ADORA3STING1PDE3BPDE3A | |
| SCHEMBL25402880 | 0.79 | ADORA3 (0.53) | HINT1ADORA3STING1PDE3BPDE3A | |
| SCHEMBL25400020 | 0.79 | ADORA3 (0.55) | HINT1ADORA3HPGDNT5ESTING1 | |
| SCHEMBL1375398 | 0.79 | ADORA3 (0.55) | HINT1ADORA3TAAR1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | SLC29A1, SLC28A1, SLC29A2 | HINT1 1411/4885ADORA3 212/4885TAAR1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.